| Insider · 13 positions | Net Shares per Quarter (+ Bought / − Sold) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Role | Shares Held ↓ | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
| Joseph K Belanoff | Chief Executive Officer | 2.6M | — | -203K | -26K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| David L Mahoney | — | 1.2M | -104K | -8K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| James N Wilson | — | 1.1M | -20K | -897K | -4K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Sean Maduck | President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission. | 169K | -81K | -99K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| William Guyer | Chief Development Officer | 110K | -40K | -58K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Atabak Mokari | Chief Financial Officer | 96K | -120K | -79K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gary Charles Robb | Chief Business Officer | 40K | -19K | -4K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Kimberly Park | — | 30K | -30K | +13K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Joshua M. Murray | — | 13K | — | +13K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Leonard G Baker JR | 13K | — | +13K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gregg H Alton | — | 13K | — | +13K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Daniel N Swisher JR | — | 13K | — | +13K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Joseph Douglas Lyon | Chief Accounting & Technology Officer | 5K | -2K | -4K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |